Page 153 - MemoriaCIBER-2018ESP

DimopouLoS m.A., DytfELD D., gRoSicKi S., moREAu p., tAKEzAKo n., HoRi m. Et AL. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 2018;379(19):1811-1822.
moRScHHAuSER f,fowLER nH,fEugiER p,BouABDALLAH R,tiLLy H,pALomBA mL Et AL.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.The New England journal of medicine. 2018;379(10):-.
pAStoR f.,BERRAonDo p.,EtxEBERRiA i.,fREDERicK J.,SAHin u.,giLBoA E. Et AL. An rna toolbox for cancer immunotherapy. Nature Reviews Drug Discovery. 2018;17(10):751-767.
KESHEt R, SzLoSAREK p, cARRAcEDo A, EREz A, cARRAcEDo pEREz ARKAitz. Rewiring urea cycle metabolism in cancer to support anabolism.Nature reviews. Cancer. 2018;:-.
coBo i.,mARtinELLi p.,fLAnDEz m.,BAKiRi L.,zHAng m.,cARRiLLo-DE-SAntA-pAu E. Et AL.
Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. Nature. 2018;554(7693):533-537
tAuRiELLo Dvf,pALomo-poncE S,StoRK D,BEREnguER-LLERgo A,BADiA-RAmEntoL J,igLESiAS m Et AL. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.Nature. 2018;554(7693):-.
SAuSSELE S.,RicHtER J.,guiLHot J.,gRuBER f.x.,HJoRtH-HAnSEn H.,ALmEiDA A. Et AL.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective,multicentre,non- randomised, trial. The Lancet Oncology. 2018;19(6):747-757.
HuEt S., tESSon B., JAiS J.-p., fELDmAn A.L., mAgnAno L., tHomAS E. Et AL. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. The Lancet Oncology. 2018;19(4):549-561.
HuRvitz S.A.,mARtin m.,SymmAnS w.f.,Jung K.H.,HuAng c.-S.,tHompSon A.m. Et AL.
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 2018;19(1):115-126.
79,2580
79,2580
50,1670
42,7840
41,5770
41,5770
36,4180
36,4180
36,4180
GruposCIBERONC. Publicaciones2018
Jefe de Grupo
P Álava Casado Enrique de
P Albanell Mestres, Joan
P Aranda Aguilar, Enrique
P Arribas López, Joaquín
P Batlle Gómez, Eduard
P Bigas Salvans, Anna
P Bosch José Francesc, Xavier
Total
Q1 D1
Institución. Centro
Provincia. Centro
11
9
5
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla. Hospital Virgen del Rocío
Sevilla
18
14
7
Consorci Mar Parc Salut de Barcelona. Hospital del Mar
Barcelona
8
6
1
Fundación para la Investigación Biomédica de Córdoba (Fibico). Hospital Universitario Reina Sofía de Córdoba
Córdoba
8
8
6
Fundación Privada Instituto de Investigación Oncológica Valle de Hebrón-VHIO
Barcelona
1
1
1
Fundación Privada Instituto de Recerca Biomédica (IRB-Barcelona)
Barcelona
12
11
7
Consorci Mar Parc Salut de Barcelona. Hospital del Mar
Barcelona
5
2
1
Fundación Idibell Hospital. Universitario de Bellvitge
Barcelona
153
CIBERONC | MEMORIA ANUAL 2018